Abstract | BACKGROUND: OBJECTIVE: METHODS: This was a multicenter, randomized, double-blind, placebo-controlled, 2-week study in patients with moderate-to-severe seasonal allergic rhinitis. The study began with a 1-week, open-label lead-in period, during which patients received fexofenadine, 60 mg twice daily. Patients who improved less than 25% to 33% with fexofenadine were randomized to treatment with (1) azelastine nasal spray, 2 sprays per nostril twice daily; (2) azelastine nasal spray, 2 sprays per nostril twice daily, plus fexofenadine, 60 mg twice daily; or (3) placebo (saline) nasal spray and placebo capsules twice daily. The primary efficacy variable was the change from baseline to day 14 in the total nasal symptom score (TNSS), consisting of runny nose, sneezing, itchy nose, and nasal congestion symptom scores. RESULTS: CONCLUSIONS:
|
Authors | Craig F LaForce, Jonathan Corren, William J Wheeler, William E Berger, Rhinitis Study Group |
Journal | Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
(Ann Allergy Asthma Immunol)
Vol. 93
Issue 2
Pg. 154-9
(Aug 2004)
ISSN: 1081-1206 [Print] United States |
PMID | 15328675
(Publication Type: Clinical Trial, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Histamine H1 Antagonists
- Phthalazines
- Terfenadine
- fexofenadine
- azelastine
|
Topics |
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Child
- Double-Blind Method
- Drug Therapy, Combination
- Female
- Histamine H1 Antagonists
(adverse effects, therapeutic use)
- Humans
- Incidence
- Male
- Middle Aged
- Phthalazines
(adverse effects, therapeutic use)
- Rhinitis, Allergic, Seasonal
(drug therapy, epidemiology)
- Terfenadine
(adverse effects, analogs & derivatives, therapeutic use)
- Treatment Outcome
|